FY2025 Earnings Forecast for KALV Issued By Leerink Partnrs

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) – Research analysts at Leerink Partnrs upped their FY2025 earnings per share (EPS) estimates for shares of KalVista Pharmaceuticals in a research note issued on Tuesday, November 11th. Leerink Partnrs analyst J. Schwartz now forecasts that the specialty pharmaceutical company will earn ($2.68) per share for the year, up from their prior forecast of ($2.96). The consensus estimate for KalVista Pharmaceuticals’ current full-year earnings is ($3.56) per share. Leerink Partnrs also issued estimates for KalVista Pharmaceuticals’ Q4 2025 earnings at ($0.64) EPS, Q1 2026 earnings at ($0.49) EPS, Q2 2026 earnings at ($0.42) EPS, Q3 2026 earnings at ($0.39) EPS, Q4 2026 earnings at ($0.29) EPS, FY2026 earnings at ($1.59) EPS and FY2027 earnings at ($0.85) EPS.

Several other research firms have also recently issued reports on KALV. Needham & Company LLC reiterated a “buy” rating and issued a $28.00 target price on shares of KalVista Pharmaceuticals in a research note on Friday, September 12th. Citigroup reiterated a “market outperform” rating on shares of KalVista Pharmaceuticals in a research report on Tuesday. Weiss Ratings restated a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a research report on Wednesday, October 8th. Citizens Jmp dropped their price target on KalVista Pharmaceuticals from $29.00 to $28.00 and set a “market outperform” rating for the company in a research note on Tuesday. Finally, JMP Securities upped their price objective on KalVista Pharmaceuticals from $27.00 to $28.00 and gave the stock a “market outperform” rating in a report on Friday, September 12th. Ten analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $26.63.

KalVista Pharmaceuticals Stock Down 1.9%

Shares of NASDAQ:KALV opened at $13.09 on Friday. The company has a 50-day moving average price of $12.22 and a two-hundred day moving average price of $12.82. The firm has a market capitalization of $661.35 million, a PE ratio of -3.32 and a beta of -0.04. KalVista Pharmaceuticals has a twelve month low of $7.30 and a twelve month high of $17.28.

KalVista Pharmaceuticals (NASDAQ:KALV) last announced its quarterly earnings data on Monday, November 10th. The specialty pharmaceutical company reported ($0.92) earnings per share for the quarter, topping the consensus estimate of ($0.96) by $0.04. The firm had revenue of $13.69 million during the quarter, compared to analysts’ expectations of $6.03 million.

Insider Buying and Selling at KalVista Pharmaceuticals

In other KalVista Pharmaceuticals news, insider Paul K. Audhya sold 2,336 shares of the company’s stock in a transaction dated Monday, August 25th. The shares were sold at an average price of $13.42, for a total transaction of $31,349.12. Following the completion of the sale, the insider directly owned 122,505 shares in the company, valued at $1,644,017.10. This represents a 1.87% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Benjamin L. Palleiko sold 3,328 shares of the firm’s stock in a transaction dated Wednesday, November 12th. The shares were sold at an average price of $11.55, for a total value of $38,438.40. Following the transaction, the chief executive officer directly owned 398,981 shares in the company, valued at $4,608,230.55. This trade represents a 0.83% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 30,184 shares of company stock valued at $413,348 over the last three months. 4.30% of the stock is currently owned by insiders.

Institutional Trading of KalVista Pharmaceuticals

A number of institutional investors have recently made changes to their positions in the stock. Earned Wealth Advisors LLC bought a new position in shares of KalVista Pharmaceuticals in the first quarter worth approximately $44,000. BNP Paribas Financial Markets raised its holdings in KalVista Pharmaceuticals by 47.0% during the 2nd quarter. BNP Paribas Financial Markets now owns 4,041 shares of the specialty pharmaceutical company’s stock valued at $46,000 after buying an additional 1,292 shares during the last quarter. CWM LLC boosted its position in KalVista Pharmaceuticals by 12,636.1% during the 1st quarter. CWM LLC now owns 4,585 shares of the specialty pharmaceutical company’s stock valued at $53,000 after buying an additional 4,549 shares during the period. Wolverine Asset Management LLC bought a new stake in shares of KalVista Pharmaceuticals in the third quarter worth about $57,000. Finally, KLP Kapitalforvaltning AS purchased a new position in KalVista Pharmaceuticals during the 3rd quarter valued at about $63,000.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).